Processing

Please wait...

Settings

Settings

1. WO1991000746 - TRANSDERMAL ADMINISTRATION OF LISURIDE

Publication Number WO/1991/000746
Publication Date 24.01.1991
International Application No. PCT/US1990/003782
International Filing Date 05.07.1990
Chapter 2 Demand Filed 08.02.1991
IPC
A61K 9/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases
A61K 31/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
48Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 47/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
CPC
A61K 31/48
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
48Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 47/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 9/0014
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0014Skin, i.e. galenical aspects of topical compositions
A61K 9/7069
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases ; ; Films; Fibres of the matrix type containing drug;
7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
703characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
7046the adhesive comprising macromolecular compounds
7069obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
Applicants
  • CYGNUS RESEARCH CORPORATION [US/US]; 400 Penobscot Drive Redwood City, CA 94063, US
Inventors
  • CHIANG, Chia-Ming; US
Agents
  • CIOTTI, Thomas, E. ; Irell & Manella 545 Middlefield Road Suite 200 Menlo Park, CA 94025, US
Priority Data
379,00012.07.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TRANSDERMAL ADMINISTRATION OF LISURIDE
(FR) ADMINISTRATION TRANSDERMIQUE DE LISURIDE
Abstract
(EN)
A laminated composite (10) for administering lisuride transdermally to treat conditions such as Parkinson's disease. The composite comprises an impermeable backing layer (11) and a reservoir layer (12) containing lisuride and a permeation enhancer combined with a pressure-sensitive adhesive with the amounts of lisuride and enhancer being sufficient to cause the lisuride to pass through the skin at a rate in excess of about one mcg/cm2/hr. The composite also includes a release liner layer (13).
(FR)
Composite stratifié (10) permettant l'administration de lisuride par voie transdermique, en vue de traiter des affections comme la maladie de Parkinson. Ce composite comprend une couche de fond imperméable (11) et une couche réservoir (12) contenant la lisuride, ainsi qu'un promoteur de perméation combinés à un adhésif autocollant, les quantités de lisuride et de promoteur étant suffisantes pour permettre le passage de la lisuride à travers la peau à une cadence supérieure à environ un mcg/cm2/h. Le composite comprend également une couche de revêtement (13) permettant la libération des substances.
Also published as
FI920147
Latest bibliographic data on file with the International Bureau